

EudraCT Team  
European Medicines Agency  
Domenico Scarlattilaan 6  
1083 HS Amsterdam  
The Netherlands

27<sup>th</sup> August 2021

**Re. EudraCT number: 2014-001571-31**

**Title:** A randomized (open-label design) parallel group, multicentre study to evaluate the safety and tolerability of two different doses of Depigoid 34% Grasses Mix, 33% *Olea europaea* and 33% *Salsola kali* 3000 DPP/ml in subjects with allergic rhinitis and rhinoconjunctivitis, with or without controlled asthma.

Dear EudraCT team,

According to your request about referenced trial result post. We confirm that clinical trial was prematurely ended; no subjects were recruited for this trial. Clinical investigators and Ethics Committees were informed accordingly.

Do not hesitate to come back to us for further information.

Yours sincerely,

Alicia Marín de Pablo  
Clinical Operations Manager,  
LETI Pharma S.L.U.  
amarin@leti.com